Publication: A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.
No Thumbnail Available
Identifiers
Date
2021-02-23
Authors
Doña, Inmaculada
Torres, Maria Jose
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley and Sons
Abstract
Hereditary angioedema (HAE) is a rare inherited chronic disease characterized by unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones, and compromising patient's life. This implies a serious health problem with significant disease burden and reduced life quality. This disease presents a great clinical variability and different endotypes, hampering diagnosis and requiring a personalized treatment. The primary mediator of swelling in most phenotypes is bradykinin, which increases vasodilation and vascular permeability by binding to the bradykinin B2 receptor.
Description
MeSH Terms
Angioedemas, Hereditary
Antibodies, Monoclonal, Humanized
Complement C1 Inhibitor Protein
Humans
Plasma Kallikrein
Antibodies, Monoclonal, Humanized
Complement C1 Inhibitor Protein
Humans
Plasma Kallikrein
DeCS Terms
Angioedemas hereditarios
Costo de enfermedad
Enfermedad crónica
Vasodilatación
Bradiquinina
Permeabilidad capilar
Costo de enfermedad
Enfermedad crónica
Vasodilatación
Bradiquinina
Permeabilidad capilar
CIE Terms
Keywords
Vasodilation, Chronic Disease, Angioedemas, Hereditary, Quality of Life, Bradykinin, Cost of Illness, Capillary Permeability, Andalusian Center for Nanomedicine and Biotechnology-BIONAND
Citation
Doña I, Torres MJ. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema. Allergy. 2021 Jun;76(6):1619-1620